Press release 7 December 2023
Today, Serca Pharmaceuticals announce the successful closing of a recent fund raising. The current round was directed towards existing shareholders in Serca Pharmaceuticals. With this closing of NOK 10.2 million, Serca Pharmaceuticals are well positioned to finish its pre-clinical development program of its lead drug candidate, 13M. These pre-clinical development activities will be the foundation for the initiation of clinical phase 1 study in 2025. The fund raising round was led by the largest shareholders in Serca Pharmaceuticals; Sarsia, Inven2 and Saturn Invest.
Press release 29 August 2023
Today, Serca Pharmaceuticals will present first-in-class strategy for game-changing, post heart-attack cardioprotection at European Society of Cardiology Congress 2023, the world’s largest cardiology congress, in Amsterdam, The Netherlands. Please find the press release here.
You can also find the following poster that was presented at the event here.
Press release 22 May 2023
Today, Serca Pharmaceuticals shared exciting data on 13-M that was presented at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023. Please find the press release here.
You can also find the following poster that was presented at the event here.